IKT vs. SEPN, CRON, AVDL, TYRA, IMTX, REPL, PLRX, PRTA, BCAX, and CRMD
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Septerna (SEPN), Cronos Group (CRON), Avadel Pharmaceuticals (AVDL), Tyra Biosciences (TYRA), Immatics (IMTX), Replimune Group (REPL), Pliant Therapeutics (PLRX), Prothena (PRTA), Bicara Therapeutics (BCAX), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.
Inhibikase Therapeutics vs.
Inhibikase Therapeutics (NYSE:IKT) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
3.8% of Inhibikase Therapeutics shares are held by institutional investors. 4.6% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Septerna's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.
Inhibikase Therapeutics received 5 more outperform votes than Septerna when rated by MarketBeat users. However, 100.00% of users gave Septerna an outperform vote while only 90.00% of users gave Inhibikase Therapeutics an outperform vote.
Septerna has lower revenue, but higher earnings than Inhibikase Therapeutics.
In the previous week, Septerna had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for Septerna and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Septerna'saverage media sentiment score.
Inhibikase Therapeutics currently has a consensus target price of $6.50, indicating a potential upside of 138.97%. Septerna has a consensus target price of $43.67, indicating a potential upside of 158.54%. Given Septerna's higher probable upside, analysts plainly believe Septerna is more favorable than Inhibikase Therapeutics.
Summary
Septerna beats Inhibikase Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:IKT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free IKT Stock Alerts